Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be performed before, during the planed radio/chemotherapy (short before brachytherapy) and 3 months after the therapy.
Conditions
Interventions
Product Name: 18F-fluoroazomycin arabinoside (18F-FAZA)
Product Code: -
Pharmaceutical Form: Intravenous infusion
Sponsors
University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA. Treatment intention for the purpose of achieving cure Age =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour. Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA. ;Secondary Objective: --;Primary end point(s): Visualisation of the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA. | — |
Countries
Austria
Outcome results
None listed